SMS Pharmaceuticals reported a strong financial year with a 47% rise in net profit to ₹101.98 crore. Revenue grew 13% to ₹886.87 crore, driven by operational efficiencies. However, the company faces an NCLT insolvency petition over a disputed ₹3.02 crore claim, which management is actively contesting.
SMS Pharmaceuticals FY26 Financial Growth and Operational Update
Net Profit jumped 47% to ₹101.98 crore; Revenue rose 13% to ₹886.87 crore.
Reader Takeaway: Strong top-line and bottom-line growth are tempered by a contested ₹3.02 crore NCLT insolvency petition.
What just happened
SMS Pharmaceuticals released its audited financial results for FY 2025-26, showing significant growth. The company reported a net profit of ₹101.98 crore, up from ₹69.14 crore in the previous year. Revenue increased to ₹886.87 crore compared to ₹782.75 crore last year. The board has also recommended a dividend of ₹0.40 per share, with a record date of September 22, 2026.
Why this matters
The company is scaling its manufacturing capabilities through a ₹280 crore capital expenditure program aimed for completion by FY27. A key focus is expanding ibuprofen capacity to 9,600 MTPA, which may strengthen its global market position. These investments are intended to drive volume and revenue growth.
Risks to watch
Investors must monitor an insolvency petition filed by M/s. Sai Sreyas Pharmaceutical Pvt. Ltd. under Section 9 of the IBC, 2016. The petitioner alleges a default of ₹3.02 crore. SMS Pharmaceuticals has formally disputed the claim, citing defective material supplies, and is defending the case at the NCLT, Hyderabad Bench.
What to track next
Watch for further legal updates from the NCLT proceedings and the progress of the company's capex projects. Management remains focused on high-value API filings, having submitted 12 DMFs and CEPs during the last fiscal year to support long-term portfolio growth.